ABSTRACT
Toxoplasma gondii (T. gondii) that can infect most warm-blooded animals and humans, is an obligate intracellular apicomplexan parasite with a wide host range. About one-third of the world’s population is infected with this parasite. While toxoplasmosis progresses asymptomatically in individuals with a strong immune system, it can cause serious clinical manifestations and death in immunocompromised individuals. The parasite is transmitted to humans through the consumption of water and food contaminated with cat feces, as well as raw or undercooked animal products, congenital infection and blood/organ transplantation. Additionally, T. gondii is often observed in farm animals such as sheep and goats. Clinical manifestations and abortions caused by T. gondii in sheep and goats lead to enormous economic loss worldwide. There is a commercial vaccine against T. gondii, called Toxovax (MSD, New Zealand) that can only be used in sheep. For these reasons, there is a need for innovative T. gondii vaccine that is harmless, easily produced, which can prevent losses and be used in all living things. Advances in immunology, molecular biology, genetic, biotechnology and proteomics bring new perspectives to vaccine studies. Studies in innovative vaccine studies against T. gondii have accelerated with the discovery of new antigens by in vitro screenings, and bioinformatic analyzes, the use of various expression systems and new adjuvant types. Recombinant protein vaccines are biotechnological vaccines that are frequently preferred due to their rapid and easy production in various expression systems, availability of very and high purity products, ease of manipulation and stimulation of both cellular and humoral immune responses. Recombinant protein vaccines, developed by biotechnological methods, are promising tools for providing a protective immune response against toxoplasmosis. In this review, an overview of the parasite complex life cycle, its pathogenesis, humoral and cellular immune responses in the host, and recombinant protein vaccine studies developed against the parasite are presented.
Keywords: Toxoplasma gondii, recombinant protein vaccines, biotechnology, immunization
References
1
Yektaeian N, Malekpour A, Atapour A, Davoodi T, Hatam G. Genetic immünization against toxoplasmosis: A review article. Microb Pathog 2021; 155: 104888.
2
Gürüz AY, Delibaş SB. Toksoplazmozis ve İmmunolojisi. Tıbbi ve Veteriner İmmunoparazitoloji, Özcel MA, İnci A, Turgay N, Köroğlu E. Editors. Turkiye Parazitol Derg 2007.p.167-94.
3
Dubey JP, Lindsay DS, Speer CA. Structures of Toxoplasma gondii tachyzoites, bradyzoites, and sporozoites and biology and development of tissue cysts. Clin Microbiol Rev 1998; 11: 267-99.
4
Wang JL, Zhang NZ, Li TT, He JJ, Elsheikha HM, Zhu XQ. Advances in the development of anti-Toxoplasma gondii vaccines: challenges, opportunities, and perspectives. Trends Parasitol 2019; 35: 239-53.
5
Lyons RE, McLeod R, Roberts CW. Toxoplasma gondii tachyzoite-bradyzoite interconversion. Trends Parasitol 2002; 18: 198-201.
6
Saadatnia G, Golkar M. A review on human toxoplasmosis. Scand J Infect Dis 2012; 44: 805-14.
7
Inceboz M, Inceboz, T. Toxoplasmosis and Neuropsychological Effects. Turkiye Parazitol Derg 2021; 45: 49-55.
8
Weiss LM, Dubey JP. Toxoplasmosis: A history of clinical observations. Int J Parasitol 2009; 39: 895-901.
9
Innes EA, Hamilton C, Garcia JL, Chryssafidis A, Smith D. A one health approach to vaccines against Toxoplasma gondii. Food Waterborne Parasitol 2019; 15: e00053.
10
Liljeqvist S, Ståhl S. Production of recombinant subunit vaccines: protein immunogens, live delivery systems and nucleic acid vaccines. J Biotechnol 1999; 73: 1-33.
11
Nascimento IP, Leite LCC. Recombinant vaccines and the development of new vaccine strategies. Braz J Med Biol Res 2012; 45: 1102-11.
12
Dubey JP. The history of Toxoplasma gondii--the first 100 years. J Eukaryot Microbiol 2008; 55: 467-75.
13
Dubey JP. Toxoplasma, Neospora, Sarcocystis, and other tissue cyst forming Coccidia of humans and animals. Parasitic Protozoa 1993; 6: 5-57.
14
Kolören Z, Dubey JP. A review of toxoplasmosis in humans and animals in Turkey. Parasitology 2020; 147: 12-28.
15
Döşkaya M, Caner A, Ajzenberg D, Değirmenci A, Dardé ML, Can H, et al. Isolation of Toxoplasma gondii strains similar to Africa 1 genotype in Turkey. Parasitol Int 2013; 62: 471-4.
16
Yucesan B, Guldemir D, Babur C, Kilic S, Cakmak A. Whole-genome sequencing of a Toxoplasma gondii strain from a Turkish isolate using next-generation sequencing technology. Acta Trop 2021; 218: 105907.
17
Attias M, Teixeira DE, Benchimol M, Vommaro RC, Crepaldi PH, De Souza W. The life-cycle of Toxoplasma gondii reviewed using animations. Parasit Vectors 2020; 13: 588.
18
Beder D, Taşbent FE. Genel Özellikleri ve Laboratuvar Tanısı ile Toxoplasma gondii Enfeksiyonları. Turkiye Parazitol Derg 2020; 44: 94-101.
19
Aguirre AA, Longcore T, Barbieri M, Dabritz H, Hill D, Klein PN, et al. The one health approach to toxoplasmosis: epidemiology, control, and prevention strategies. Ecohealth 2019; 16: 378-90.
20
Jones JL, Kruszon-Moran D, Sanders-Lewis K, Wilson M. Toxoplasma gondii infection in the United States, 1999 2004, decline from the prior decade. Am J Trop Med Hyg 2007; 77: 405-10.
21
Hodge JM, Coghill AE, Kim Y, Bender N, Smith‐Warner SA, Gapstur S, et al. Toxoplasma gondii infection and the risk of adult glioma in two prospective studies. Int J Cancer 2021.
22
Al-Malki ES. Toxoplasmosis: stages of the protozoan life cycle and risk assessment in humans and animals for an enhanced awareness and an improved socio-economic status. Saudi J Biol Sci 2021; 28: 962-9.
23
Tenter AM, Heckeroth AR, Weiss LM. Toxoplasma gondii: from animals to humans. Int J Parasitol 2000; 30: 1217-58.
24
Djurković-Djaković O, Dupouy-Camet J, Van der Giessen J, Dubey JP. Toxoplasmosis: overview from a one health perspective. Food Waterborne Parasitol 2019; 15: e00054.
25
Havelaar AH, Kirk MD, Torgerson PR, Gibb HJ, Hald T, Lake RJ, et al. World Health Organization global estimates and regional comparisons of the burden of foodborne disease in 2010. PLoS Med 2015; 12: e1001923.
26
Pleyer U, Gross U, Schlüter D, Wilking H, Seeber F. Toxoplasmosis in Germany. Dtsch Arztebl Int 2019; 116: 435-44.
27
Ocak S, Zeteroglu S, Ozer C, Dolapcioglu K, Gungoren A. Seroprevalence of Toxoplasma gondii, rubella and cytomegalovirus among pregnant women in southern Turkey. Scand J Infect Dis. 2007; 39: 231-4.
28
Kayman T, Kayman M. Kayseri’deki Gebelerde Toksoplasmoz Seroprevalans. Perinatoloji Derg 2015; 18: 92-6.
29
Toklu GD. Antibodies frequency against Toxoplasmosis, Rubella Virus and Cytomegalovirus in pregnant women. J Clin Anal Med 2013; 4: 38-40.
30
Karakavuk M, Can H, Gül A, Döşkaya AD, Alak SE, Ün C, et al. GRA8 DNA vaccine formulations protect against chronic toxoplasmosis. Microb Pathog 2021; 158: 105016.
31
Ajioka JW, Fitzpatrick JM. Reitter CP. Toxoplasma gondii genomics: shedding light on pathogenesis and chemotherapy. Expert Rev Mol Med 2001; 2001: 1-19.
32
Zhang Y, Lai BS, Juhas M, Zhang Y. Toxoplasma gondii secretory proteins and their role in invasion and pathogenesis. Microbiol Res 2019; 227: 126293.
33
Weiss LM, Kim K. Toxoplasma gondii, The Model Apicomplexan: Perspectives and Methods, Elsevier 2011; pp. 800.
34
Talevich E, Kannan N. Structural and evolutionary adaptation of rhoptry kinases and pseudokinases, a family of coccidian virulence factors. BMC Evol Biol 2013; 13: 117.
35
Rezaei F, Sarvi S, Sharif M, Hejazi SH, Sattar Pagheh A, Aghayan SA, et al. A systematic review of Toxoplasma gondii antigens to find the best vaccine candidates for immünization. Microb Pathog 2019; 126: 172-84.
36
Sibley LD. Invasion and intracellular survival by protozoan parasites. Immunol Rev 2011; 240: 72-91.
37
Mohamed RM, Aosai F, Chen M, Mun HS, Norose K, Belal US, et al. Induction of protective immunity by DNA vaccination with Toxoplasma gondii HSP70, HSP30 and SAG1 genes. Vaccine 2003; 21: 2852-61.
38
Kikumura A, Fang H, Mun HS, Uemura N, Makino M, Sayama Y, et al. Protective immünity against lethal anaphylactic reaction in Toxoplasma gondii-infected mice by DNA vaccination with T. gondii-derived heat shock protein 70 gene. Parasitol Int 2010; 59: 105-11.
39
Döşkaya M, Liang L, Jain A, Can H, İz SG, Felgner PL, et al. Discovery of new Toxoplasma gondii antigenic proteins using a high throughput protein microarray approach screening sera of murine model infected orally with oocysts and tissue cysts. Parasit Vectors 2018; 11: 393.
40
Filisetti D, Candolfi E. Immune response to Toxoplasma gondii. Ann Ist Super Sanita 2004; 40: 71-80.
41
Henriquez FL, Woods S, Cong H, McLeod R, Roberts CW. Immunogenetics of Toxoplasma gondii informs vaccine design. Trends Parasitol 2010; 26: 550-5.
42
Pier GB, Lyczak JB, Wetzler LM. Immunology, infection, and immunity. American Society for Microbiology, Washington D.C. 2004.p.697.
43
Xiao J, Yolken RH. Strain hypothesis of Toxoplasma gondii infection on the outcome of human diseases. Acta Physiol (Oxf) 2015; 213: 828-45.
44
Munoz M, Liesenfeld O, Heimesaat MM. Immunology of Toxoplasma gondii. Immunol Rev 2011; 240: 269-85.
45
Hunter CA, Sibley LD. Modulation of innate immunity by Toxoplasma gondii virulence effectors. Nat Rev Microbiol 2012; 10: 766-78.
46
Karakavuk M, Aldemir D, Mercier A, Atalay Şahar E, Can H, Murat JB, et al. Prevalence of toxoplasmosis and genetic characterization of Toxoplasma gondii strains isolated in wild birds of prey and their relation with previously isolated strains from Turkey. PLoS One 2018; 13: e0196159.
47
Hansson M, Nygren P, Ståhl S. Design and production of recombinant subunit vaccines. Biotechnol Appl Biochem 2000; 32: 95-107.
48
Andersson C. Production and delivery of recombinant subunit vaccines, Department of Biotechnology Royal Institute of Technology (KTH), Sweden, 2000; p. 92.
49
Demain AL, Vaishnav P. Production of recombinant proteins by microbes and higher organisms. Biotechnol Adv 2009; 27: 297-306.
50
Andersen DC, Krummen L. Recombinant protein expression for therapeutic applications. Curr Opin Biotechnol 2002; 13: 117-23.
51
Hudu SA, Shinkafi SH, Shuaibu U. An overview of recombinant vaccine technology, adjuvants and vaccine delivery methods. Int J Pharm Pharm Sci 2016; 8: 19-24.
52
Shi S, Zhu H, Xia X, Liang Z, Ma X, Sun B. Vaccine adjuvants: Understanding the structure and mechanism of adjuvanticity. Vaccine 2019; 37: 3167-78.
53
Reed SG, Orr MT, Fox CB. Key roles of adjuvants in modern vaccines. Nat Med 2013; 19: 1597-608.
54
Pollet J, Chen WH, Strych U. Recombinant protein vaccines, a proven approach against coronavirus pandemics. Adv Drug Deliv Rev 2021; 170: 71-82.
55
Petrovsky N, Aguilar JC. Vaccine adjuvants: current state and future trends. Immunol Cell Biol 2004; 82: 488-96.
56
Petersen E, Nielsen HV, Christiansen L, Spenter J. Immunization with E. coli produced recombinant T. gondii SAG1 with alum as adjuvant protect mice against lethal infection with Toxoplasma gondii. Vaccine 1998; 16: 1283-9.
57
Letscher Bru V, Villard O, Risse B, Zauke M, Klein JP, Kien TT. Protective effect of vaccination with a combination of recombinant surface antigen 1 and interleukin 12 against toxoplasmosis in mice. Infect Immun 1998; 66: 4503-6.
58
Supply P, Sutton P, Coughlan SN, Bilo K, Saman E, Trees AJ, et al. Immunogenicity of recombinant BCG producing the GRA1 antigen from Toxoplasma gondii. Vaccine 1999; 17: 705-14.
59
Haumont M, Delhaye L, Garcia L, Margarita J, Pasqualina M, Véronique D, et al. Protective immunity against congenital toxoplasmosis with recombinant SAG1 protein in a guinea pig model, Infect Immun 2000; 68: 4948-53.
60
Mishima M, Xuan X, Shioda A, Omata Y, Fujisaki K, Nagasawa H, et al. Modified protection against Toxoplasma gondii lethal infection and brain cyst formation by vaccination with SAG2 and SRS1. J Vet Med Sci 2001; 63: 433-8.
61
Letscher-Bru V, Pfaff AW, Abou-Bacar A, Filisetti D, Antoni E, Villard O, et al. Vaccination with Toxoplasma gondii SAG-1 protein is protective against congenital toxoplasmosis in BALB/c mice but not in CBA/J mice. Infect Immun 2003; 71: 6615-9.
62
Martin V, Supanitsky A, Echeverria P, Litwin S, Tanos T, Roodt, A, et al. Recombinant GRA4 or ROP2 protein combined with alum or the GRA4 gene provides partial protection in chronic murine models of toxoplasmosis. Clin Diagn Lab Immunol 2004; 11: 704-10.
63
Echeverria P, Miguel N, Costas M, Angel S. Potent antigen-specific immunity to Toxoplasma gondii in adjuvant-free vaccination system using Rop2-Leishmania infantum Hsp83 fusion protein. Vaccine 2006; 24: 4102-10.
64
Golkar M, Shokrgozar MA, Rafati S, Musset K, Assmar M, Sadaie, R, et al. Evaluation of protective effect of recombinant dense granule antigens GRA2 and GRA6 formulated in monophosphoryl lipid A (MPL) adjuvant against Toxoplasma chronic infection in mice. Vaccine 2007; 25: 4301-11.
65
Zhou H, Gu Q, Zhao Q, Zhang J, Cong H, Li Y, et al. Toxoplasma gondii: expression and characterization of a recombinant protein containing SAG1 and GRA2 in Pichia pastoris. Parasitol Res 2007; 100: 829-35.
66
Döşkaya M, Kalantari-Dehaghi M, Walsh CM, Hiszczyńska-Sawicka E, Davies DH, et al. GRA1 protein vaccine confers better immune response compared to codon-optimized GRA1 DNA vaccine. Vaccine 2007; 25: 1824-37.
67
Wang HL, Liu Q, Liu K, Zhong W, Gao S, Jiang L, An N. Immune response induced by recombinant Mycobacterium bovis BCG expressing ROP2 gene of Toxoplasma gondii. Parasitol Int 2007; 56: 263-8.
68
Cuppari AF, Sanchez V, Ledesma B, Frank FM, Goldman A, Angel SO, et al. Toxoplasma gondii protease inhibitor-1 (TgPI-1) is a novel vaccine candidate against toxoplasmosis. Vaccine 2008; 26: 5040-5.
69
Igarashi M, Kano F, Tamekuni K, Machado RZ, Navarro IT, Vidotto O, et al. Toxoplasma gondii: evaluation of an intranasal vaccine using recombinant proteins against brain cyst formation in BALB/c mice. Exp Parasitol 2008; 118: 386-92.
70
Gatkowska J, Gasior A, Kur J, Dlugonska H. Toxoplasma gondii: chimeric Dr fimbriae as a recombinant vaccine against toxoplasmosis. Exp Parasitol 2008; 118: 266-70.
71
Dziadek B, Gatkowska J, Brzostek A, Dziadek J, Dzitko K, Dlugonska H. Toxoplasma gondii: the immunogenic and protective efficacy of recombinant ROP2 and ROP4 rhoptry proteins in murine experimental toxoplasmosis. Exp Parasitol 2009; 123: 81-9
72
Fang R, Feng H, Nie H, Wang L, Tu P, Song Q, et al. Construction and immunogenicity of pseudotype baculovirus expressing Toxoplasma gondii SAG1 protein in BALB/c mice model. Vaccine 2010; 28: 1803-7.
73
Machado A, Caetanoa B, Barbosa R, Salgado AP, Rabelo R, Garcia, C, et al. Prime and boost immunization with influenza and adenovirus encoding the Toxoplasma gondii surface antigen 2 (SAG2) induces strong protective immunity. Vaccine 2010; 28: 3247-56.
74
Rashid I, Hedli D, Moire N, Pierre J, Debierre-Grockiego, F, Dimier-Poisson I, et al. Immunological responses induced by a DNA vaccine expressing RON4 and by immunogenic recombinant protein RON4 failed to protect mice against chronic toxoplasmosis. Vaccine 2011; 29: 8838-46.
75
Sánchez VR, Pitkowski MN, Fernández Cuppari AV, Rodríguez FM, Fenoy IM, Frank FM, et al. Combination of CpG-oligodeoxynucleotides with recombinant ROP2 or GRA4 proteins induces protective immunity against Toxoplasma gondii infection. Exp Parasitol 2011; 128: 448-53.
76
Dziadek B, Gatkowska J, Brzostek A Dziadek J, Dzitko K, Grzybowski M, et al. Evaluation of three recombinant multi-antigenic vaccines composed of surface and secretory antigens of Toxoplasma gondii in murine models of experimental toxoplasmosis. Vaccine 2011; 29: 821-30.
77
Wang Y, Wang M, Wang G, Pang A, Fu B, Yin H, et al. Increased survival time in mice vaccinated with a branched lysine multiple antigenic peptide containing B- and T-cell epitopes from T. gondii antigens. Vaccine 2011; 29: 8619-23.
78
Dziadek B, Gatkowska J, Grzybowski M, Dziadek J, Dzitko K, Dlugonska H. Toxoplasma gondii: the vaccine potential of three trivalent antigen-cocktails composed of recombinant ROP2, ROP4, GRA4 and SAG1 proteins against chronic toxoplasmosis in BALB/c mice. Exp Parasitol 2012; 131: 133-8.
79
Del L, Yácono M, Farran I, Becher ML, Sander V, Sánchez VR, Martin V, et al. A chloroplast-derived Toxoplasma gondii GRA4 antigen used as an oral vaccine protects against toxoplasmosis in mice. Plant Biotechnol J 2012; 10: 1136-44.
80
Min J, Qu D, Li C, Song X, Zhao Q, Li XA, et al. Enhancement of protective immune responses induced by Toxoplasma gondii dense granule antigen 7 (GRA7) against toxoplasmosis in mice using a prime-boost vaccination strategy. Vaccine 2012; 30: 5631-6.
81
Zheng B, Lu S, Tong Q, Kong Q, Lou D. The virulence-related rhoptry protein 5 (ROP5) of Toxoplasma gondii is a novel vaccine candidate against toxoplasmosis in mice. Vaccine 2013; 31: 4578-84.
82
Qu D, Han J, Du A. Enhancement of protective immune response to recombinant Toxoplasma gondii ROP18 antigen by ginsenoside Re. Exp Parasitol 2013; 135: 234-9.
83
Yu Q, Huang X, Gong P, Zhang Q, Li J, Zhang G, et al. Protective immunity induced by a recombinant BCG vaccine encoding the cyclophilin gene of Toxoplasma gondii. Vaccine 2013; 31: 6065-71.
84
Wang HL, Li YQ, Yin LT, Meng XL, Guo M, Zhang JH, et al. Toxoplasma gondii Protein Disulfide Isomerase (TgPDI) is a novel vaccine candidate against toxoplasmosis. PLoS One 2013; 8: e70884.
85
Yin LT, Hao HX, Wang HL, Zhang JH, Meng XL, Yin GR. Intranasal immunisation with recombinant Toxoplasma gondii actin partly protects mice against Toxoplasmosis. PLoS One 2013; 8: e82765.
86
Chuang SC, Ko JC, Chen CP, Du JT, Yang CD. Induction of long-lasting protective immunity against Toxoplasma gondii in BALB/c mice by recombinant surface antigen 1 protein encapsulated in poly (lactide-co-glycolide) microparticles. Parasit Vectors 2013; 6: 34.
87
Chuang SC, Ko JC, Chen CP, Du JT, Yang CD. Encapsulation of chimeric protein rSAG1/2 into poly(lactide-co-glycolide) microparticles induces long-term protective immunity against Toxoplasma gondii in mice. Exp Parasitol 2013; 134: 430-7.
88
Mendes ÉA, Fonseca FG, Casério BM, Colina JP, Gazzinelli RT, Caetano BC. Recombinant vaccines against T. gondii: comparison between homologous and heterologous vaccination protocols using two viral vectors expressing SAG1. PLoS One 2013; 8: e63201.
89
Wang HL, Pang M, Yin LT, Zhang JH, Meng XL, Yu BF, et al. Intranasal immunisation of the recombinant Toxoplasma gondii receptor for activated C kinase 1 partly protects mice against T. gondii infection. Acta Trop 2014; 137: 58-66.
90
Wang HL, Zhang TE, Yin LT, Pang M, Guan L, Liu H, et al. Partial protective effect of intranasal immunization with recombinant Toxoplasma gondii Rhoptry Protein 17 against toxoplasmosis in mice. PLoS One 2014; 9: e108377.
91
Chuang SC, Yang CD. Sustained release of recombinant surface antigen 2 (rSAG2) from poly(lactide-co-glycolide) microparticles extends protective cell-mediated immunity against Toxoplasma gondii in mice. Parasitology 2014; 1-10.
92
Tanaka S, Kuroda Y, Ihara F, Nishimura M, Hiasa J, Kojima N, et al. Vaccination with profilin encapsulated in oligomannose-coated liposomes induces significant protective immunity against Toxoplasma gondii. Vaccine 2014; 32: 1781-5.
93
Sun X, Mei M, Zhang X, Han F, Jia B, Wei X, et al. The extracellular matrix protein mindin as a novel adjuvant elicits stronger immune responses for rBAG1, rSRS4and rSRS9 antigens of Toxoplasma gondii in BALB/c mice. BMC Infect Dis 2014; 14: 429.
94
Zhang TE, Yin LT, Li RH, Wang HL, Meng XL, Yin GR. Protective immunity induced by peptides of AMA1, RON2 and RON4 containing T-and B-cell epitopes via an intranasal route against toxoplasmosis in mice. Parasit Vectors 2015; 8: 15.
95
Wagner A, Schabussova I, Ruttkowski B, Peschke R, Kur J, Kundi M, et al. Prime-boost vaccination with Toxoplasma lysate antigen, but not with a mixture of recombinant protein antigens, leads to reduction of brain cyst formation in BALB/c mice. PLoS One 2015; 10: e0126334.
96
Lu G, Wang L, Zhou A, Han Y, Guo J, Song P, et al. Epitope analysis, expression and protection of SAG5A vaccine against Toxoplasma gondii. Acta Trop 2015; 146: 66-72.
97
Xu Y, Zhang NZ, Wang M, Dong H, Feng SY, Guo HC, et al. A long-lasting protective immunity against chronic toxoplasmosis in mice induced by recombinant rhoptry proteins encapsulated in poly (lactide-co-glycolide) microparticles. Parasitol Res 2015; 114: 4195-203.
98
Albarracín RM, Becher ML, Farran I, Sander VA, Corigliano MG, Yácono ML, et al. The fusion of Toxoplasma gondii SAG1 vaccine candidate to Leishmania infantum heat shock protein 83‐kDa improves expression levels in tobacco chloroplasts. Biotechnol J 2015; 10: 748-59.
99
Sánchez VR, Fenoy IM, Picchio MS, Soto AS, Arcon N, Goldman A, et al. Homologous prime-boost strategy with TgPI-1 improves the immune response and protects highly susceptible mice against chronic Toxoplasma gondii infection. Acta Trop 2015; 150: 159-65.
100
Sonaimuthu P, Ching XT, Fong MY, Kalyanasundaram R, Lau YL. Induction of protective immunity against toxoplasmosis in BALB/c mice vaccinated with Toxoplasma gondii Rhoptry-1. Front Microbiol 2016; 7: 808.
101
Wang HL, Wen LM, Pei YJ, Wang F, Yin LT, Bai JZ, et al. Recombinant Toxoplasma gondii phosphoglycerate mutase 2 confers protective immunity against toxoplasmosis in BALB/c mice. Parasite 2016; 23: 12.
102
Zhang NZ, Xu Y, Wang M, Chen J, Huang SY, Gao Q, et al. Vaccination with Toxoplasma gondii calcium-dependent protein kinase 6 and rhoptry protein 18 encapsulated in poly (lactide-co-glycolide) microspheres induces long-term protective immunity in mice. BMC Infect Dis 2016; 16: 168.
103
Liu Z, Yuan F, Yang Y, Yin L, Liu Y, Wang Y, et al. Partial protective immunity against toxoplasmosis in mice elicited by recombinant Toxoplasma gondii malate dehydrogenase. Vaccine 2016; 34: 989-94.
104
Gedik Y, İz SG, Can H, Döşkaya AD, Gürhan SİD, Gürüz Y, et al. Immunogenic multistage recombinant protein vaccine confers partial protection against experimental toxoplasmosis mimicking natural infection in murine model. Trials in Vaccinology 2016; 5: 15-23.
105
Liu Z, Yin L, Li Y, Yuan F, Zhang X, Ma J, et al. Intranasal immunization with recombinant Toxoplasma gondii actin depolymerizing factor confers protective efficacy against toxoplasmosis in mice. BMC Immunol 2016; 17: 37.
106
Tang X, Yin G, Qin M, Tao G, Suo J, Liu X, et al. Transgenic Eimeria tenella as a vaccine vehicle: expressing TgSAG1 elicits protective immunity against Toxoplasma gondii infections in chickens and mice. Sci Rep 2016; 6: 29379.
107
Ching XT, Fong MY, Lau YL. Evaluation of immunoprotection conferred by the subunit vaccines of GRA2 and GRA5 against acute toxoplasmosis in BALB/c mice. Front Microbiol 2016; 7: 609.
108
Allahyari M, Mohabati R, Amiri S, Rastaghi ARE, Babaie J, Mahdavi M, et al. Synergistic effect of rSAG1 and rGRA2 antigens formulated in PLGA microspheres in eliciting immune protection against Toxoplasama gondii. Exp Parasitol 2016; 170: 236-46.
109
El Bissati K, Chentoufi AA, Krishack PA, Zhou Y, Woods S, Dubey JP, et al. Adjuvanted multi-epitope vaccines protect HLA-A* 11: 01 transgenic mice against Toxoplasma gondii. JCI Insight 2016; 1: e85955.
110
Wang M, Yang XY, Zhang NZ, Zhang DL, Zhu XQ. Evaluation of protective immune responses induced by recombinant TrxLp and ENO2 proteins against Toxoplasma gondii infection in BALB/c mice. Biomed Res Int 2016; 2016: 3571962.
111
Lee DH, Lee SH, Kim AR, Quan FS. Virus-like nanoparticle vaccine confers protection against Toxoplasma gondii. PLoS One 2016; 11: e0161231.
112
Fereig RM, Nishikawa Y. Peroxiredoxin 3 promotes IL-12 production from macrophages and partially protects mice against infection with Toxoplasma gondii. Parasitol Int 2016; 65: 741-8.
113
Nabi H, Rashid I, Ahmad N, Durrani A, Akbar H, Islam S, et al. Induction of specific humoral immune response in mice immunized with ROP18 nanospheres from Toxoplasma gondii. Parasitol Res 2017; 116: 359-70.
114
Czarnewski P, Araújo EC, Oliveira MC, Mineo TW, Silva NM. Recombinant TgHSP70 immunization protects against Toxoplasma gondii brain cyst formation by enhancing inducible nitric oxide expression. Front Cell Infect Microbiol 2017; 7: 142.
115
Zulpo DL, Igarashi M, Sammi AS, Santos JRD, Sasse JP, Cunha I ALD, et al. rROP2 from Toxoplasma gondii as a potential vaccine against oocyst shedding in domestic cats. Rev Bras Parasitol Vet 2017; 26: 67-73.
116
Fereig RM, Kuroda Y, Terkawi MA, Mahmoud ME, Nishikawa Y. Immunization with Toxoplasma gondii peroxiredoxin 1 induces protective immunity against toxoplasmosis in mice. PLoS One 2017; 12: e0176324.
117
Rashid I, Moiré N, Héraut B, Dimier-Poisson I, Mévélec MN. Enhancement of the protective efficacy of a ROP18 vaccine against chronic toxoplasmosis by nasal route. Med Microbiol Immunol 2017; 206: 53-62.
118
Wang S, Zhang Z, Wang Y, Gadahi JA, Xu L, Yan R, et al. Toxoplasma gondii elongation factor 1-alpha (TgEF-1a) is a novel vaccine candidate antigen against toxoplasmosis. Front Microbiol 2017; 8: 168.
119
Zhuo X, Sun H, Wang S, Guo X, Ding H, Yang Y, et al. Ginseng Stem-and-Leaf Saponin (GSLS)-enhanced protective immune responses induced by Toxoplasma gondii Heat Shocked Protein 70 (HSP70) against toxoplasmosis in mice. J Parasitol 2017; 103: 111-7.
120
Oledzka G, Bo L, Hiszczynska-Sawicka E, Gelder FB, Kur J, McFarlane RG. Toxoplasma gondii: Immunological response of sheep to injections of recombinant SAG1, SAG2, GRA1 proteins coupled to the non-toxic microparticle muramyl dipeptide. Small Rum Res 2017; 150: 111-7.
121
Wang L J, Xiao T, Xu C, Li J, Liu GZ, Yin K, et al. Protective immune response against Toxoplasma gondii elicited by a novel yeast-based vaccine with microneme protein 16. Vaccine 2018; 36: 3943-8.
122
Lakhrif Z, Moreau A, Hérault B, Di-Tommaso A, Juste M, Moiré N, et al. Targeted delivery of Toxoplasma gondii antigens to dendritic cells promote immunogenicity and protective efficiency against toxoplasmosis. Front Immunol 2018; 9: 317.
123
Hajissa K, Zakaria R, Suppian R, Mohamed Z. Immunogenicity of Multiepitope Vaccine Candidate against Toxoplasma gondii Infection in BALB/c Mice. Iran J Parasitol 2018; 13: 215-24.
124
Roozbehani M, Falak R, Mohammadi M, Hemphill A, Razmjou E, Reza Meamar A, et al. Characterization of a multi-epitope peptide with selective MHC-binding capabilities encapsulated in PLGA nanoparticles as a novel vaccine candidate against Toxoplasma gondii infection. Vaccine 2018; 36: 6124-32.
125
Lee SH, Kang HJ, Lee DH, Kang SM, Quan FS. Virus-like particle vaccines expressing Toxoplasma gondii rhoptry protein 18 and microneme protein 8 provide enhanced protection. Vaccine 2018; 36: 5692-700.
126
Kang HJ, Lee SH, Chu KB, Lee DH, Quan FS. Virus-like particles expressing Toxoplasma gondii rhoptry protein 18 induces better protection than rhoptry protein 4 against T. gondii infection. Korean J Parasitol 2018; 56: 429-35.
127
Picchio MS, Sánchez VR, Arcon N, Soto AS, Sibilia MP, Aldirico MDLA, et al. Vaccine potential of antigen cocktails composed of recombinant Toxoplasma gondii TgPI-1, ROP2 and GRA4 proteins against chronic toxoplasmosis in C3H mice. Exp Parasitol 2018; 185: 62-70.
128
Naeem H, Sana M, Islam S, Khan M, Riaz F, Zafar Z, et al. Induction of Th1 type-oriented humoral response through intranasal immunization of mice with SAG1-Toxoplasma gondii polymeric nanospheres. Artif Cells Nanomed Biotechnol 2018; 46(Suppl 2): 1025-34.
129
Pagheh AS, Sarvi S, Gholami S, Asgarian-Omran H, Valadan R, Hassannia H, et al. Protective efficacy induced by DNA prime and recombinant protein boost vaccination with Toxoplasma gondii GRA14 in mice. Microb Pathog 2019; 134: 103601.
130
Wu M, An R, Chen Y, Chen T, Wen H, Yan Q, et al. Vaccination with recombinant Toxoplasma gondii CDPK3 induces protective immunity against experimental toxoplasmosis. Acta Trop 2019; 199: 105148.
131
Huang SY, Chen K, Wang JL, Yang B, Zhu XQ. Evaluation of protective immunity induced by recombinant calcium-dependent protein kinase 1 (TgCDPK1) protein against acute toxoplasmosis in mice. Microb Pathog 2019; 133: 103560.
132
Liu K, Wen H, Cai H, Wu M, An R, Chu D, et al. Protective effect against toxoplasmosis in BALB/c mice vaccinated with Toxoplasma gondii macrophage migration inhibitory factor. Front Microbiol 2019; 10: 813.
133
Lee SH, Kang HJ, Lee DH, Quan FS. Protective immunity induced by incorporating multiple antigenic proteins of Toxoplasma gondii into influenza virus-like particles. Front Immunol 2019; 9: 3073.
134
Kang HJ, Lee SH, Kim MJ, Chu KB, Lee DH, Chopra M, et al. Influenza virus-like particles presenting both Toxoplasma gondii ROP4 and ROP13 enhance protection against T. gondii Infection. Pharmaceutics 2019; 11: 342.
135
Kang HJ, Chu KB, Lee SH, Kim MJ, Park H, Jin H, et al. Virus-like Particle Vaccine Containing Toxoplasma gondii Rhoptry Protein 13 Induces Protection against T. gondii ME49 Infection in Mice. Korean J Parasitol 2019; 57: 543-7.
136
Kang HJ, Chu KB, Lee SH, Kim MJ, Park H, Jin H, et al. Toxoplasma gondii virus‐like particle vaccination alleviates inflammatory response in the brain upon T. gondii infection. Parasite Immunol 2020; 42: e12716.
137
Choi WH, Park JS. Immunogenicity and Protective Effect of a Virus-Like Particle Containing the SAG1 Antigen of Toxoplasma gondii as a Potential Vaccine Candidate for Toxoplasmosis. Biomedicines 2020; 8: 91.
138
Kim MJ, Lee SH, Kang HJ, Chu KB, Park H, Jin H, et al. Virus-like particle vaccine displaying Toxoplasma gondii apical membrane antigen 1 induces protection against T. gondii ME49 infection in mice. Microb Pathog 2020; 142: 104090.
139
Li ZY, Guo HT, Calderón-Mantilla G, He JJ, Wang JL, Bonev BB, et al. Immunostimulatory efficacy and protective potential of putative TgERK7 protein in mice experimentally infected by Toxoplasma gondii. Int J Med Microbiol 2020; 310: 151432.
140
Atalay Şahar E, Can H, İz S, Döşkaya A, Kalantari-Dehaghi M, Deveci R, et al. Development of a hexavalent recombinant protein vaccine adjuvanted with Montanide ISA 50V and determination of its protective efficacy against acute toxoplasmosis. BMC Infect Dis 2020; 20: 493.
141
Kang HJ, Chu KB, Kim MJ, Lee S H, Park H, Jin H, et al. Protective immunity induced by CpG ODN‐adjuvanted virus‐like particles containing Toxoplasma gondii proteins. Parasite Immunol 2021; 43: e12799.
142
Dodangeh S, Fasihi-Ramandi M, Daryani A, Valadan R, Asgarian-Omran H, Hosseininejad Z, et al. Protective efficacy by a novel multi-epitope vaccine, including MIC3, ROP8, and SAG1, against acute Toxoplasma gondii infection in BALB/c mice. Microb Pathog 2021; 153: 104764.
143
Arcon N, Picchio MS, Fenoy IM, Moretta RE, Soto AS, Sibilia MDP, et al. Synergistic effect of GRA7 and profilin proteins in vaccination against chronic Toxoplasma gondii infection. Vaccine 2021; 39: 933-42.
144
Yu Z, Lu Y, Liu Z, Aleem MT, Liu J, Luo J, et al. Recombinant Toxoplasma gondii ribosomal protein P2 modulates the functions of murine macrophages in vitro and provides immunity against acute toxoplasmosis in vivo. Vaccines (Basel) 2021; 9: 357.
